NeOnc Technologies Holdings, Inc. NTHI
2.99 USD -0.18 (-5.68%)
Nov 5, 2026, 12:30 PM EST
2.91 Day range 3.12
2.50 52-week range 12.00
- YTD
- -63.85%
- 1 year
- -72.84%
- Market cap
- 86.13M
- Revenue (ttm)
- 70.46K
- EPS (ttm)
- -2.13
- Shares out
- 22.56M
- YTD return
- -63.85%
- 1-year return
- -72.84%
- Volume
- 56.37K
- Avg volume
- 211.73K
- Open
- 3.12
- Previous close
- 3.17
- Day's range
- 2.91 – 3.12
- 52-week range
- 2.50 – 12.00
2Y -9.12 (-75.31%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -100.00%
- Free cash flow
- 1.21M
- Total cash
- 31.86K
- Total debt
- 6.61M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NTHI Revenue — quarterly 0
NTHI Net income — quarterly -14.24M
NTHI EPS — quarterly -0.58
About NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
- Country
- United States
- Website
- neonctech.com
News
NeOnc Technologies Q3 EPS $(0.28) Misses $(0.24) Estimate 
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress 
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage 
NeOnc Technologies To Present Data From Intranasal NEO100 And Oral NEO212 Programs In Two Posters, At 31st Annual Meeting And Education Day Of SNO 
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology 
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage 
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries 
12 Health Care Stocks Moving In Friday's Intraday Session 
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue 
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
Your note
Sign in to keep a note on NTHI — it syncs with the Stock Master app.